CN101977628A - α7烟碱激动剂和抗精神病药的组合 - Google Patents

α7烟碱激动剂和抗精神病药的组合 Download PDF

Info

Publication number
CN101977628A
CN101977628A CN2009801102033A CN200980110203A CN101977628A CN 101977628 A CN101977628 A CN 101977628A CN 2009801102033 A CN2009801102033 A CN 2009801102033A CN 200980110203 A CN200980110203 A CN 200980110203A CN 101977628 A CN101977628 A CN 101977628A
Authority
CN
China
Prior art keywords
methyl
azabicyclo
oct
pyridine radicals
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801102033A
Other languages
English (en)
Chinese (zh)
Inventor
M·本切里夫
G·J·加托
T·豪瑟
K·G·乔丹
S·R·莱特克沃斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CN101977628A publication Critical patent/CN101977628A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2009801102033A 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合 Pending CN101977628A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
US61/028,282 2008-02-13
PCT/US2009/034062 WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013100500436A Division CN103143023A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合

Publications (1)

Publication Number Publication Date
CN101977628A true CN101977628A (zh) 2011-02-16

Family

ID=40902222

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801102033A Pending CN101977628A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合
CN2013100500436A Pending CN103143023A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013100500436A Pending CN103143023A (zh) 2008-02-13 2009-02-13 α7烟碱激动剂和抗精神病药的组合

Country Status (25)

Country Link
US (1) US20110059947A1 (cg-RX-API-DMAC7.html)
EP (2) EP2254598B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011511845A (cg-RX-API-DMAC7.html)
KR (1) KR20100113163A (cg-RX-API-DMAC7.html)
CN (2) CN101977628A (cg-RX-API-DMAC7.html)
AU (1) AU2009214625A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0907570A2 (cg-RX-API-DMAC7.html)
CA (1) CA2715268A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290706A2 (cg-RX-API-DMAC7.html)
CY (1) CY1114492T1 (cg-RX-API-DMAC7.html)
DK (1) DK2254598T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010471A (cg-RX-API-DMAC7.html)
ES (1) ES2430622T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130749T1 (cg-RX-API-DMAC7.html)
IL (1) IL207389A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010008875A (cg-RX-API-DMAC7.html)
NZ (1) NZ587312A (cg-RX-API-DMAC7.html)
PL (1) PL2254598T3 (cg-RX-API-DMAC7.html)
PT (1) PT2254598E (cg-RX-API-DMAC7.html)
RS (1) RS52941B (cg-RX-API-DMAC7.html)
RU (1) RU2481123C2 (cg-RX-API-DMAC7.html)
SG (1) SG188144A1 (cg-RX-API-DMAC7.html)
SI (1) SI2254598T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009102962A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201005999B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN108727416A (zh) * 2017-04-20 2018-11-02 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
CN117480169A (zh) * 2021-01-08 2024-01-30 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2619205B1 (en) 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrate of an azaadamantane derivative
EP2665478A1 (en) * 2011-01-18 2013-11-27 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
MX2015004285A (es) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
BR0016168A (pt) * 1999-12-10 2002-08-20 Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
AU2001266100B9 (en) * 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
JP2006510664A (ja) * 2002-12-06 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 1−アザビシクロ[2.2.2]オクト置換フロ[2,3−c]ピリジニルカルボキサミドの結晶性フマル酸塩及び該塩を含む組成物並びにその製造方法
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727416A (zh) * 2017-04-20 2018-11-02 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN117480169A (zh) * 2021-01-08 2024-01-30 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物

Also Published As

Publication number Publication date
WO2009102962A2 (en) 2009-08-20
PL2254598T3 (pl) 2013-12-31
EP2254598B1 (en) 2013-07-10
JP2011511845A (ja) 2011-04-14
IL207389A0 (en) 2010-12-30
PT2254598E (pt) 2013-10-16
SG188144A1 (en) 2013-03-28
CO6290706A2 (es) 2011-06-20
ES2430622T3 (es) 2013-11-21
RS52941B (sr) 2014-02-28
WO2009102962A3 (en) 2009-10-08
HRP20130749T1 (en) 2013-10-11
AU2009214625A1 (en) 2009-08-20
SI2254598T1 (sl) 2013-10-30
RU2010137787A (ru) 2012-03-20
EP2254598A2 (en) 2010-12-01
ZA201005999B (en) 2011-05-25
NZ587312A (en) 2011-12-22
KR20100113163A (ko) 2010-10-20
ECSP10010471A (es) 2010-10-30
MX2010008875A (es) 2010-08-31
DK2254598T3 (da) 2013-07-29
CA2715268A1 (en) 2009-08-20
BRPI0907570A2 (pt) 2019-09-24
CN103143023A (zh) 2013-06-12
HK1147954A1 (en) 2011-08-26
RU2481123C2 (ru) 2013-05-10
US20110059947A1 (en) 2011-03-10
EP2633868A1 (en) 2013-09-04
CY1114492T1 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
EP2254598B1 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
Dwomoh et al. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
US20100178277A1 (en) Methods and compositions for stimulating cells
KR20190124722A (ko) 신경계 장애의 치료에서 사용하기 위한 d-메타돈 및 이의 유도체
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
AU2021200697A1 (en) Use of pridopidine for the treatment of anxiety and depression
US20070293538A1 (en) Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
JP2018520187A (ja) 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
Chagraoui et al. 5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders
JP2022511266A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
CN102365269A (zh) 用于治疗认知缺损的新药物
Ding et al. Ketamine as a rapid-acting antidepressant: A scoping review of mechanisms and efficacy in treatment-resistant depression
HK1185794A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
HK1147954B (en) Combination of alpha 7 nicotinic agonists and antipsychotics
JP5714572B2 (ja) 精神障害およびその症状の治療のためのkcnqカリウムチャネル活性の調節方法
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
Hori Developmental Effects of Bilateral Ventral Hippocampal Lesions on Neocortical [capital Delta] FosB Expression and Cognition: Reversal of Cognitive Deficits by Darbepoetin Alfa But Not Clozapine
Goff et al. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110216